Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.48 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.47 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.46 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.46 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | GID4 | Q8IVV7 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 3/20 | 0.43 |
| ▸ | KDM1A | O60341 | 2/20 | 0.43 |
| ▸ | MAOB | P27338 | 2/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.42 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.42 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31494195 | 1.00 | MEN1 (0.59) | MEN1KMT2AMKNK1ADRA2CCHRNB2 | |
| SCHEMBL6181098 | 1.00 | MEN1 (0.59) | MEN1KMT2AMKNK1ADRA2CCHRNB2 | |
| SCHEMBL11508634 | 0.95 | MEN1 (0.55) | MEN1KMT2AMKNK1ADRA2CCHRNB2 | |
| SCHEMBL3348073 | 0.95 | MEN1 (0.54) | MEN1KMT2AMKNK1ADRA2CCHRNB2 | |
| Hydrochloric Acid SCHEMBL11509626 | 0.93 | MEN1 (0.54) | MEN1KMT2AMKNK1ADRA2CCHRNB2 | |
| SCHEMBL8542490 | 0.93 | MEN1 (0.53) | MEN1KMT2AMKNK1ADRA2CCHRNB2 | |
| SCHEMBL4599631 | 0.93 | MEN1 (0.53) | MEN1KMT2AMKNK1ADRA2CCHRNB2 | |
| SCHEMBL12536772 | 0.90 | MEN1 (0.50) | MEN1KMT2AMKNK1ADRA2CCHRNB2 | |
| SCHEMBL16610729 | 0.81 | MEN1 (0.55) | MEN1KMT2ACHRNB2CHRNA7CHRNA4 | |
| SCHEMBL21427 | 0.81 | NQO1 (0.47) | MEN1KMT2AMKNK1CHRNB2CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250206734-A1 | BICYCLIC HETEROCYCLES AS MRGPRX2 ANTAGONISTS | INCYTE CORPORATION | 2025-06-26 | — | — | US | disclosed |
| EP-4545515-A1 | BCL-2 INHIBITORS | BeiGene Switzerland GmbH (CH) | 2025-04-30 | — | — | EP | disclosed |
| US-20240376104-A1 | Bcl-2 Inhibitors | BEIGENE LTD. (KY) | 2024-11-14 | — | — | US | disclosed |
| US-12077536-B2 | BCL-2 inhibitors | BEIGENE, LTD. (KY) | 2024-09-03 | — | — | US | disclosed |
| US-20240115711-A1 | Novel Bifunctional Molecules For Targeted Protein Degradation | AMPHISTA THERAPEUTICS LIMITED (GB) | 2024-04-11 | — | — | US | disclosed |
| CN-117683029-A | Bcl-2 inhibitors | 百济神州有限公司 | 2024-03-12 | — | — | CN | disclosed |
| CN-117430601-A | Bcl-2 inhibitors | 百济神州有限公司 | 2024-01-23 | — | — | CN | disclosed |
| CN-112437772-B | Bcl-2 inhibitors | 百济神州有限公司 | 2023-11-21 | — | — | CN | disclosed |
| EP-4263511-A1 | NOVEL BIFUNCTIONAL MOLECULES FOR TARGETED PROTEIN DEGRADATION | Amphista Therapeutics Ltd (GB) | 2023-10-25 | — | — | EP | disclosed |
| CN-116897150-A | Novel bifunctional molecules for protein-targeted degradation | 安菲斯塔治疗有限公司 | 2023-10-17 | — | — | CN | disclosed |
| EP-1165510-B1 | 1-ARENESULFONYL-2-ARYL-PYRROLIDINE AND PIPERIDINE DERIVATIVES FOR THE TREATMENT OF CNS DISORDERS | HOFFMANN LA ROCHE (CH) | 2005-09-28 | — | — | EP | disclosed |
| EP-1165510-A1 | 1-ARENESULFONYL-2-ARYL-PYRROLIDINE AND PIPERIDINE DERIVATIVES FOR THE TREATMENT OF CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-01-02 | — | — | EP | disclosed |
| US-6284785-B1 | HAVING ACTIVITY AS LIGANDS OF METABOTROPIC GLUTAMATE RECEPTORS | HOFFMANN- LA ROCHE INC. | 2001-09-04 | — | — | US | disclosed |
| WO-2000058285-A1 | 1-ARENESULFONYL-2-ARYL-PYRROLIDINE AND PIPERIDINE DERIVATIVES FOR THE TREATMENT OF CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2000-10-05 | — | — | WO | disclosed |
| EP-0671388-B1 | (Pyrrolidinyl)phenyl carbamates and intermediate compounds, processes for their preparation and their use as medicaments | HOECHST MARION ROUSSEL INC (US) | 1998-06-10 | — | — | EP | disclosed |
| US-5591856-A | CHEMICAL INTERMEDIATES, TREATMENT OF ALZHEIMER'S DISEASE | HOECHST ROUSSEL PHARMACEUTICALS INC. (US) | 1997-01-07 | — | — | US | disclosed |
| US-5554750-A | TO RELIEVE MEMORY DYSFUNCTIONS; TREATMENT OF ALZHEMER*S | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1996-09-10 | — | — | US | disclosed |
| EP-0671388-A1 | (Pyrrolidinyl)phenyl carbamates and intermediate compounds, processes for their preparation and their use as medicaments | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1995-09-13 | — | — | EP | disclosed |
| US-5405845-A | Administering to relieve memory dysfunction; treatment of Alzheimer's disease | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1995-04-11 | — | — | US | disclosed |
| US-5338739-A | Memory dysfunction relieving compounds | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1994-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12077536-B2 | BCL-2 inhibitors | BCL2, BCL2L1, BCL2L2 | MEN1 3803/4885KMT2A 2464/4885MKNK1 607/4885 |
| US-20240376104-A1 | Bcl-2 Inhibitors | BCL2, BCL2L1, BCL2L2 | MEN1 3803/4885KMT2A 2464/4885MKNK1 607/4885 |
| US-20250206734-A1 | BICYCLIC HETEROCYCLES AS MRGPRX2 ANTAGONISTS | MRGPRX2, MRGPRX1, MRGPRX4 | MEN1 1828/4885KMT2A 4304/4885MKNK1 1822/4885 |
| US-20240115711-A1 | Novel Bifunctional Molecules For Targeted Protein Degradation | PSMG3, MYCBP2, PSME2 | MEN1 3151/4885KMT2A 3634/4885MKNK1 1368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.